



Europäisches Patentamt  
European Patent Office  
Office européen des brevets

(11) Publication number:

**0 321 128  
A1**

(12)

## EUROPEAN PATENT APPLICATION

(21) Application number: 88311445.6

(51) Int. Cl. 4: **A61K 37/02 , //(A61K37/02,  
31:20)**

(22) Date of filing: 02.12.88

(30) Priority: 14.12.87 GB 8729153

(43) Date of publication of application:  
21.06.89 Bulletin 89/25

(84) Designated Contracting States:  
AT BE CH DE ES FR GB GR IT LI LU NL SE

(71) Applicant: EFAMOL HOLDINGS PLC  
Efamol House Woodbridge Meadows  
Guildford Surrey GU1 1BA(GB)

(72) Inventor: Horrobin, David Frederick Scotia  
Pharmaceuticals  
Ltd. Efamol House Woodbridge Meadows  
Guildford Surrey GU1 1BA(GB)

(74) Representative: Caro, William Egerton et al  
J. MILLER & CO. Lincoln House 296-302 High  
Holborn  
London WC1V 7JH(GB)

(54) Fatty acid compositions.

(57) Composition of a cyclosporin and GLA or DGLA or derivative thereof convertible in the body thereto alone or in a pharmaceutical diluent or carrier.

**EP 0 321 128 A1**

**FATTY ACID COMPOSITIONS****FIELD OF INVENTION**

This invention relates to fatty acid compositions.

5

**GENERAL BACKGROUND**

Cyclosporin is an important new drug developed to produce suppression of the immune system in patients receiving organ transplants, such as kidneys, hearts and livers. It is now apparent that it may have much wider uses in conditions such as psoriasis, rheumatoid arthritis, and early diabetes. It is probable but not yet certain that its effectiveness is in those conditions in which the disease process is related to abnormal functioning of part of the immune system.

Cyclosporin is an unusual cyclic peptide containing 11 amino acids. One of these is a nine carbon, olefinically unsaturated compound. Modified cyclosporins also have biological activity, but the olefinic amino acid appears important in this activity. Cyclosporin and its biologically active analogues (the cyclosporin-like compounds) all bind to a family of proteins known as cyclophilins which are found in the thymus gland, lymphocytes and other tissues. Biological activity of the cyclosporins and related compounds appears to be dependent on their ability to bind specifically to cyclophilins.

Unfortunately cyclosporin has a number of side effects, one of which is of particular importance and restricts use of the drug in disease states of only mild to moderate severity. This is that cyclosporin produces impairment of renal function. Although the mechanism of this renal damage is not yet certain, it appears that constriction of blood vessels, so reducing blood flow to the kidney, plays an important part. The mechanism of this vasoconstrictor action is also uncertain but is believed to involve increased production of thromboxane A<sub>2</sub>, a highly active vasoconstrictor derived from arachidonic acid.

It has been proposed that the renal side effects of cyclosporin may be alleviated by administering the drug in combination with metabolites of alpha-linolenic acid, namely eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) which are found in some abundance in fish oils. In animals there is experimental evidence that the treatment can lower the level of thromboxane A<sub>2</sub> (TXA<sub>2</sub> measured as its metabolite, thromboxane B<sub>2</sub>) in the kidney, and so reduce vasoconstriction and renal damage.

**ESSENTIAL FATTY ACIDS RELATIONSHIPS AND DISCUSSION**

There are two series of essential fatty acids (EFAs) which are not inter-convertible in the mammalian body but are related as shown in the following outline of essential fatty acid metabolism:-

40

45

50

TABLE 1

<u>n-6</u>	<u>n-3</u>
18:2 delta-9,12 (linoleic acid)	18:3 delta-9,12,15 (alpha-linolenic acid)
delta-6 desaturase	
18:3 delta-6,9,12 (gamma-linolenic acid)	18:4 delta-6,9,12,15
elongation	
20:3 delta-8,11,14 (dihomo-gamma-linolenic acid)	20:4 delta-8,11,14,17
delta-5 desaturase	
20:4 delta-5,8,11,14 (arachidonic acid)	20:5 delta-5,8,11,14,17
elongation	
22:4 delta-7,10,13,16 (adrenic acid)	22:5 delta-7,10,13,16,19
delta-4 desaturase	
22:5 delta-4,7,10,13,16	22:6 delta-4,7,10,13,16,19

The present invention depends on newly appreciated relationships of cyclosporins with essential fatty acids. As noted above, it has been proposed to ameliorate the adverse effects of cyclosporins by the countervailing effect of the fatty acids found in fish oils on TXA<sub>2</sub> levels. However, the fatty acids found in fish oils not only reduce the amount of potentially harmful vasoconstrictive thromboxane A<sub>2</sub> formed from arachidonic acid, they also reduce the production of vasodilator metabolites such as prostaglandin E<sub>1</sub> (PGE<sub>1</sub>) from DGLA and prostacyclin and PGE<sub>2</sub> from arachidonic acid. The fish oil fatty acids, are therefore not the best agents to use in conjunction with cyclosporin, at least when employed alone. DGLA however, and unlike arachidonic acid, produces metabolites which are vasodilator or biologically inert in this regard, and therefore consistently has vasodilator actions. Both DGLA and arachidonic acid are found in some abundance in renal tissue. The vasodilator metabolites of both DGLA and arachidonic acid are believed to be important in the maintenance of normal renal blood flow. Since DGLA has no vasoconstrictor

metabolites, it is best to employ an agent which raises levels of DGLA in the kidneys.

While DGLA can be formed from dietary linoleic acid by the pathway shown, the first step in the conversion is extremely slow in humans and in fact rate limiting. Administration of dietary linoleic acid has not been shown to be successful in raising human GLA concentrations: in contrast, by-passing the rate-limiting step by giving GLA, does raise human DGLA levels. In addition to being inherently slow, the formation of GLA is inhibited by a wide variety of factors, including ageing, atopic disorders, diabetes, catecholamines, alcohol, cholesterol, and zinc deficiency.

Administration of GLA or DGLA is an efficient way of raising the concentrations of DGLA in humans. Some of the DGLA is converted to arachidonic acid, but this step is also relatively slow, and the ratio of DGLA to arachidonic acid rises after such administration. Moreover, administration of GLA has been found to inhibit the formation of thromboxane B<sub>2</sub> in patients with certain disorders (see Table 2 below). In these studies the GLA was administered in the form of evening primrose oil. The mechanism of inhibition of thromboxane formation is uncertain. However, DGLA can give rise to PGE<sub>1</sub>, which in turn elevates concentrations of cyclic AMP. Cyclic AMP inhibits the enzyme phospholipase A<sub>2</sub> which is known to affect the mobilisation of arachidonic acid from phospholipids and hence the conversion of arachidonic acid to thromboxane and other metabolites.

TABLE 2

THROMBOXANE B <sub>2</sub> PRODUCTION FROM AGGREGATING PLATELETS			
	ON PLACEBO	ON GLA	
Patients with premenstrual syndrome	186 ± 44 ng/ml	141 ± 59 ng/ml	p<0.01
Patients with Raynaud's syndrome	208 ± 36 ng/ml	179 ± 18 ng/ml	p<0.05

#### THE INVENTION

We therefore propose the administration of GLA or DGLA in association (including chemical combination) with cyclosporin and derivatives to counter their side effects, especially the renal side effects. This will be achieved by increasing the formation of vasodilator metabolites from DGLA, and possibly reducing thromboxane formation from arachidonic acid.

Additionally the invention extends to a method of making a medicament for countering the side effects of cyclosporins characterised by the use of the fatty acids as the active medicament together with the method of countering the side effects of cyclosporins characterised by administering such fatty acids to a person suffering from or at risk of such side effects.

The GLA or DGLA may be optionally combined with EPA, 22:5 n-3 and DHA, the fatty acids found in fish oils. These fatty acids will also reduce thromboxane. These fatty acids will, further, increase the ratio of DGLA to arachidonic acid, by inhibiting the enzyme 5-desaturase, which converts DGLA to arachidonic acid.

GLA, DGLA, EPA, 22:5 n-3 and DHA may each be administered in doses of 1mg to 100g per day, preferably, 50mg to 10g per day. They may be given once per day or in divided doses through the 24-hour period.

Cyclosporin and its related compounds may be administered in doses of 0.1 to 200mg/kg/day (approx. 5mg to 15g/day), preferably 5-20 mg/kg/day (approx. 0.25 to 1.5g/day).

Both the fatty acids and the cyclosporins may be administered orally or parenterally or by other convenient routes. For use in skin diseases, topical administration may be possible, using preparations of cyclosporin containing 0.1ng to 100 mg, preferably 0.1ng to 1mg per ml, and preparations of fatty acids containing 0.1ng to 100 mg, preferably 0.1ng to 10mg per ml. The fatty acids and cyclosporins may also be administered at different times and by different routes but as cyclosporin is strongly hydrophobic, for topical, and for example for oral and parenteral administration, the cyclosporins may conveniently be actually dissolved in the fatty acids.

The term cyclosporins covers not only cyclosporin itself, but any derivative of cyclosporin and compound which has cyclosporin-like activity, shown to be related to cyclosporin by reason of its ability to bind selectively to cyclophilins.

The fatty acids can moreover be administered in the forms of glycerides, salts, esters, amides, or any other pharmaceutically acceptable form which results in a rise in the level of the fatty acid in body tissues

by conversion in the body thereto and reference to EFAS herein includes such forms.

Their equivalence is demonstrated by entry into the pathway quoted herein, as evidenced by effects corresponding to those of the acids themselves or their natural glyceride esters. Thus, indirect identification of useful derivatives is by their having the valuable effect in the body of the acid itself, but conversion can be shown directly by gas chromatographic analysis of concentrations in blood, body fat, or other tissue by standard techniques, for example those of Pellick et al, page 23, "Analysis of Lipids and Lipoproteins " Ed. Perkins, American Oil Chemists Society, Champaign, Illinois, United States of America.

In outline the method is suitably that plasma samples (1 ml) are extracted with chloroform:methanol (2:1). The extract is filtered through sodium sulphate, evaporated to dryness, and taken up in 0.5 ml chloroform:methanol. The lipid fractions are separated by thin layer chromatography or silica gel plates. The phospholipid fraction, taken to reflect essential fatty acid contents most sensitively, is methylated using boron trifluoride-methanol. The resulting methyl esters of the fatty acids are separated and measured using a Hewlett-Packard 5880 gas chromatograph with a six foot column packed with 10% silar on chromosorb WAW 106/230. The carrier gas is helium (30 ml/min). Oven temperature is programmed to rise from 165 °C to 190 °C at 2 °C/min. Detector temperature is 220 °C and injector temperature 200 °C. Retention times and peak areas are automatically computed by Hewlett-Packard Level 4 Integrator. Peaks are identified by comparison with standard fatty acid methyl esters.

## 20 PACKS

If it is not desired to have compositions comprising different active materials together, packs may be prepared comprising the materials presented for separate, or part joint and part separate administration in the appropriate relative amounts, and use of such packs is within the purview of this invention.

## DIETARY COMPOSITIONS

The invention is chiefly described in terms of methods of treatment and pharmaceutical compositions, but it will be understood that the gamma-linolenic and other acids, being in the nature of dietary supplements, can be incorporated in a dietary margarine or other foodstuffs for use by those taking cyclosporin.

## 35 FORMS AND SOURCES OF GAMMA-LINOLENIC AND OTHER ACIDS

Convenient physiologically equivalent derivatives of gamma-linolenic acid and dihomogamma-linolenic acid for use according to the invention as with the other acids, includes salts, amides, esters including glyceride esters and alkyl (e.g. C<sub>1</sub> to C<sub>4</sub>) esters, and phospholipids.

If desired, pharmaceutical compositions may be produced for use in the invention by associating the natural or synthetic acids, as such or as derivatives, with an acceptable pharmaceutical vehicle. It is, however, at present convenient to provide at least the gamma-linolenic acid in the form of an available oil having a high gamma-linolenic acid content, hence reference to "oil" herein.

At the present time known natural sources of oils having a high gamma-linolenic acid content are few (there are no known natural sources of significant amounts of dihomogamma-linolenic acid). One source of oils currently available is the seed of Evening Primrose species such as *Oenothera biennis* L. and *Oenothera Lamarckiana*, the oil extract therefrom containing gamma-linolenic acid (about 8%) and linoleic acid (about 72%) in the form of their glycerides, together with other glycerides (percentages based on total fatty acids). Other sources of gamma-linolenic acids are Borage species such as *Borago officinalis* which, though current yield per acre is low, provide a richer source of gamma-linolenic acid than *Oenothera* oil. Recent studies on fungi which can be cultivated by fermentation promise a fungal oil source.

The oil is extracted from the seed by one of the conventional methods of extraction such as cold pressure, screw pressure after partially cooking the seed, or solvent extraction.

Fractionation of a typical sample of this oil in the form of methyl esters shows the relative proportions:

Palmitate	6.15
Stearate	1.6
Oleate	10.15
Linoleate	72.6
Gamma-linolenate	8.9

5

The seed oil extracts referred to above can be used as such or can, for example, if desired, be fractionated to yield an oily composition containing the tri-glycerides of gamma-linolenic and linoleic acids as the main fatty acid components, the gamma-linolenic acid content being, if desired, a major proportion. Seed oil extracts appear to have a stabilising effect upon dihomogamma-linolenic acid if present.

10

#### SOURCES OF OTHER ACIDS

15

Natural sources of 22:4 and 22:5 n-6 acids include adrenal glands (22:5) and kidneys (22:4) obtained from slaughter houses, and 22:4 in the fat of the American Snapping Turtle. The n-3 acids are available from fish oils, particularly 20:5 n-3 and 22:6 n-3.

The acids can be isolated from these sources by, for example, saponification under mild non-oxidising conditions followed by preparative gas liquid chromatography. Synthesis of the acids is difficult but not impossible and provides another source.

20

#### PHARMACEUTICAL PRESENTATION

25

The compositions are conveniently in a form suitable for oral, rectal or parenteral administration in a suitable pharmaceutical vehicle, as discussed in detail, for example, in Williams British Patent Specification No. 1,082,624, to which reference may be made, and in any case very well known generally for any particular kind of preparation. Thus, for example, tablets, capsules, ingestible liquid or powder preparations can be prepared as required, and topical preparations also when the gamma-linolenic acid or other acids are absorbed through the skin. Injectable solutions of hydrolysed Oenothera oil may be prepared using albumin to solubilise the free acid.

30

Advantageously, a preservative is incorporated into the preparation. Alpha-tocopherol in concentration of about 0.1% by weight has been found suitable for the purpose.

35

It will be understood that the absolute quantity of active materials present in any dosage unit should not exceed that appropriate to the rate and manner of administration to be employed but on the other hand should also desirably be adequate to allow the desired rate of administration to be achieved by a small number of doses. The rate of administration will moreover depend on the precise pharmacological action desired.

40

#### EXAMPLES

The following examples, made up according to conventional techniques except as to the active ingredients, illustrate the invention in its various forms.

45

#### EXAMPLE 1

50

##### For oral administration

Soft gelatine capsules containing the following combinations of cyclosporin and fatty acids.

55

	Cyclosporin	GLA	DGLA	EPA	DHA
A	30 mg	200 mg			
B	30 mg	300 mg		200 mg	
C	30 mg	100 mg	100 mg	100 mg	50 mg
D	30 mg		300 mg		
E	100 mg	400 mg			
F	100 mg	300 mg		100 mg	
G	100 mg	100 mg	100 mg	100 mg	50 mg
H	100 mg	400 mg		200 mg	

Emulsions containing the above amounts of active ingredients in each 5 ml of emulsion instead of in a capsule.

## EXAMPLE 2

### For parenteral administration

Sterile ampoules containing the amounts of active ingredients in A to H above in a vegetable oil base.

## EXAMPLE 3

### For intravenous administration

Emulsions prepared in 5 ml sterile ampoules containing the quantities of active ingredients specified in A to H which can be added to standard solutions of intravenous lipids.

## EXAMPLE 4

### For topical administration

Ointments and creams made using standard techniques containing active ingredients as follows, by weight:-

	Cyclosporin	GLA	DGLA	EPA	DHA
A	0.01%	2%		0.5%	
B	0.05%	4%	1%	1%	0.3%
C	0.1%	5%			
D	0.15%		2%		
E	0.1%		2%	1%	
F	0.05%	3%		1%	0.5%

## Claims

1. Composition of a cyclosporin and GLA or DGLA or derivative thereof convertible in the body thereto alone or in a pharmaceutical diluent or carrier.

2. Composition according to claim 1 comprising also an n-3 essential fatty acid selected from the 20:5, 22:5 and 22:6 acids or their derivatives convertible in the body thereto.

3. Composition according to claim 1 or claim 2 presented in dosage form for administration of 1 mg to 100 g, preferably 50 mg to 10 g, of the or each fatty acid and 5 mg to 15 g, preferably 250 mg to 1.5 g, of the cyclosporin, per day.

4. Composition according to claim 1 or 2 for topical administration, comprising 0.1 ng to 100 mg, preferably 0.1 ng to 10 mg per mil of the or each fatty acid and 0.1 ng to 100 mg, preferably 0.1 ng to 1 mg per mil of cyclosporin.

5. The use of the active components specified in claim 1, 2 or 3 for the preparation of a medicament for countering the side effects, especially the renal side effects, of the administration of cyclosporin.

6. The use of the essential fatty acid or acids specified in claim 1, 2 or 3 for the preparation of a medicament for countering the side effects, especially the renal side effects, of the administration of cyclosporin.

7. A method of countering the side effects, especially the renal side effects, of administration of cyclosporin wherein the components of the composition according to claim 1, 2 or 3 are administered together or successively to a person suffering from or at risk of such side effects.

20

25

30

35

40

45

50

55





European Patent  
Office

**PARTIAL EUROPEAN SEARCH REPORT**  
which under Rule 45 of the European Patent Convention  
shall be considered, for the purposes of subsequent  
proceedings, as the European search report

Application number  
**EP 88 31 1445**

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
A	WO-A-87 06 463 (BRIGHAM AND WOMEN'S HOSPITAL) * Page 40, claims 1-3 * --	1-6	A 61 K 37/02// (A 61 K 37/02 A 61 K 31:20)
A	EP-A-0 087 865 (EFAMOL LTD.)		
A	EP-A-0 086 092 (SMITHKLINE BECKMAN CORP.) -----		
			TECHNICAL FIELDS SEARCHED (Int. Cl.4)
			A 61 K
<b>INCOMPLETE SEARCH</b> <p>The Search Division considers that the present European patent application does not comply with the provisions of the European Patent Convention to such an extent that it is not possible to carry out a meaningful search into the state of the art on the basis of some of the claims.</p> <p>Claims searched completely: 1-6  Claims searched incompletely:  Claims not searched: 7  Reason for the limitation of the search:</p> <p>Method for treatment of the human or animal body by surgery or therapy  (See art. 52(4) of the European Patent Convention)</p>			
Place of search <b>The Hague</b>		Date of completion of the search <b>28-03-1989</b>	Examiner <b>BRINKMANN</b>
<b>CATEGORY OF CITED DOCUMENTS</b> X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			